AnaptysBio, Inc. (NASDAQ:ANAB) – Research analysts at Wedbush lifted their FY2017 earnings per share (EPS) estimates for AnaptysBio in a report released on Thursday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($1.59) per share for the year, up from their previous estimate of ($1.76). Wedbush has a “Positive” rating and a $82.00 price target on the stock. Wedbush also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.35) EPS, Q1 2018 earnings at ($0.41) EPS, Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.50) EPS, Q4 2018 earnings at ($0.54) EPS, FY2018 earnings at ($1.90) EPS, FY2019 earnings at ($2.19) EPS, FY2020 earnings at ($2.06) EPS and FY2021 earnings at ($0.69) EPS.
Several other research firms have also commented on ANAB. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target for the company in a report on Friday. JMP Securities boosted their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Credit Suisse Group boosted their price target on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Finally, Royal Bank Of Canada initiated coverage on shares of AnaptysBio in a report on Thursday, September 14th. They issued an “outperform” rating and a $40.00 price target for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. AnaptysBio currently has an average rating of “Buy” and an average price target of $81.00.
Shares of AnaptysBio (NASDAQ:ANAB) opened at $71.23 on Monday. AnaptysBio has a twelve month low of $15.17 and a twelve month high of $74.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.02.
Several institutional investors have recently modified their holdings of the company. Citadel Advisors LLC purchased a new position in shares of AnaptysBio in the 3rd quarter worth approximately $20,406,000. Artal Group S.A. grew its position in shares of AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the last quarter. Vanguard Group Inc. grew its position in shares of AnaptysBio by 22.6% in the 2nd quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after buying an additional 37,932 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of AnaptysBio by 210.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock worth $6,363,000 after buying an additional 124,219 shares during the last quarter. Finally, VHCP Management II LLC purchased a new position in shares of AnaptysBio in the 3rd quarter worth approximately $5,856,000. 59.04% of the stock is currently owned by hedge funds and other institutional investors.
In other news, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.